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1. Introduction
  Myocardial ischemia/reperfusion injury often occurs 
after thrombolysis, percutaneous transluminal coronary 
angioplasty, and coronary artery bypass surgery for acute 
myocardial infarction. The underlying pathophysiological 
mechanism is that the expression of cytokines, in particular 
cell surface adhesion molecules induces the aggregation 
and adherence of inflammatory cells, resulting in immune-
mediated injury to histiocytes[1,2], which greatly influences 
the therapeutic effects and prognosis in patients with 
myocardial infarction. Peroxisome proliferator-activated 
receptor gamma (PPAR-毭) is mainly expressed in 
adipose tissue and immune system and closely related to 
adipocyte differentiation, insulin resistance and organism 
immunity[3-5]. Rosiglitazone can regulate insulin gene 
transcription, which is involved in glucose production, 
transport and utilization, by activating PPAR-毭 and it can 
also alleviate myocardial ischemia/reperfusion injury by 
inhibiting inflammatory reaction, improving endothelial 
function and reducing oxidative stress[6-8]. Whether 
rosiglitazone exhibits protective effects on myocardial 
ischemia/reperfusion injury remains poorly understood. 
This study investigated this problem, hoping to provide 
new thoughts for clinical treatment of myocardial ischemia/
reperfusion injury and achieve favorable economic and 
social benefits.  
2. Materials and methods 
2.1. Animals and reagents
  Male Japanese big-ear rabbits, weighing (2.50依0.25) kg, 
were provided by Laboratory Animal Center, Zhengzhou 
University, China.
Rosiglitazone was produced by Shanghai No.1 Biochemical 
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and Pharmaceutical Co., Ltd., China (batch No. 06050211). 
It was used together with physiological saline in the clinic 
and should be sterilized before use. Glucose injection 
was produced by Ji’nan Limin Pharmaceutical Co., Ltd., 
China (batch No. 0512547) and sodium chloride injection by 
Shenyang Zhiying Pharmaceutical Factory, China (batch No. 
06080204). Superoxide dismutase (SOD), malondialdehyde 
(MDA), nitric oxide (NO), glutathione peroxidase (GSH-
Px), and endothelin (ET) kits were purchased from Nanjing 
Jiancheng Bioengineering Institute, China. 
2.2. Instruments 
  The following instruments were used in this study: 7170A 
full-automatic biochemical analyzer (Hitachi, Japan), 721 
visible spectrophotometer (Shanghai Precision & Scientific 
Instrument Co., Ltd., China), UV300 ultraviolet-visible 
spectrophotometer, K15-C low-temperature ultracentrifuge 
(Beijing Medical Centrifuge Factor, China), MDFU40865 low 
temperature and ultra low temperature freezer, HX-200 
animal respirator, SHH.7121.600 electrothermal constant-
temperature water tank (Beijing Ever Light Medical 
Equipment Co., Ltd., China), MC-ASCENT enzyme reader, 
electronic balance, DYY-6C electrophoresis apparatus, 
CH20 optical microscope (Olympus, Shinjuku-ku, Tokyo, 
Japan), CIAS-1000 image analyzer, RF-535 fluorescence 
detector, LC-9A high performance liquid chromatograph 
(Shimadzu, Japan), C-35A microscope (Olympus), and IX-70 
inverted fluorescence microscope. 
2.3. Methods 
2.3.1. Establishment of acute myocardial ischemia/reperfusion 
injury models in rabbits 
  Following anesthesia by 20% urethane (1 g/kg), chest hair 
was sheared, and an incision was made along the midsternal 
line and started over the clavicle and till the xiphoid process 
of the sternum. The second, third and fourth ribs were 
interrupted at the left sternal border and the pericardium 
was cut open to expose the heart. A 2/0 silk suture was 
introduced into the root region of the circumflex branch of 
left coronary artery for later ligation 
2.3.2. Grouping and drug administration 
  Forty-eight rabbits were randomly divided into four groups. 
In the sham operation group, the suture was introduced into 
the circumflex branch of the left coronary artery and twisted, 
and ligation was not performed; before surgery, rabbits were 
raised with common pellet feeds for 3 d. In the ischemia/
reperfusion group, 30-minute ischemia followed by 60 min 
reperfusion was performed, and before surgery, rabbits were 
also raised with common pellet feeds for 3 d. Based on the 
procedure in the ischemia/reperfusion group, 3 mg and 0.5 mg
rosiglitazone was orally administered in the rosiglitazone 
high-dose and low-dose groups, respectively. On the day 
of surgery, the circumflex branch of the left coronary artery 
was ligated in the latter three groups. When an obvious 
ST-segment elevation, a sign of successful ligation, was 
observed in the electrocardiogram, 1-hour reperfusion was 
performed. Then blood was taken from the common carotid 
artery through the use of heparin anticoagulation tube for 
detection of biochemical indices. 
2.3.3. Index detection 
  Plasma plasma cardiac troponin 栺 (CTn栺), creatinine 
kinase-MB (CK-MB) and C-reactive protein (hsCRP) levels 
were detected in the blood immediately taken from the 
common carotid artery. 
  After 10-minute centrifugation at 2 500 r/min, the 
supernatant of the common carotid artery blood was 
collected for detection of plasma total superoxide dismutase 
(T-SOD), GSH-Px, MDA, NO and ET levels. 
2.3.4. Sample preparation
  Following washes with fixing solution, myocardial tissue on 
the left ventricular anterior wall was dissected into several 
strips, fixed in the fixing solution, rinsed with 0.09 mmol/L 
KH2PO4 for 15 min, and preserved in KH2PO4. Strip-shaped 
tissue was hydrated in a graded series of ethanol, cleared by 
xylene, and embedded by paraffin. Then part of tissue was 
used for immunohistochemical detection and the remainder 
was sliced, stained with hematoxylin-eosin, and observed 
under the optical microscope. 
2.3.5. Immunohistochemistry
  Paraffin sections were dehydrated, dewaxed with xylene 
and dehydrated alcohol, retrieved by citric acid antigen, 
enveloped, hybridized, developed and mounted by gum.  
2.4. Statistical analysis 
  All data were statistically processed using SPSS 17.0 
software. Measurement data were expressed as mean依SD. 
Q-test was used for difference comparison between two 
groups and one-way analysis of variance for difference 
comparison among multiple groups. A level of P<0.05 
indicates significant difference and P<0.05 highly significant 
difference. Pathomorphological data were analyzed by 
contrast description.
3. Results 
3.1. Effects of rosiglitazone on plasma CTn栺, CK-MB and 
hsCRP levels in rabbits with myocardial ischemia/reperfusion 
injury 
  Compared with sham operation group, plasma CTn栺, CK-
MB and hsCRP levels in the ischemia/reperfusion group 
were significantly increased. Plasma CTn栺, CK-MB and 
hsCRP levels in the rosiglitazone high-dose group and 
rosiglitazone low-dose group were significantly lower than 
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in the ischemia/reperfusion group (Table 1). 
Table 1
Plasma CTn栺, CK-MB and hsCRP levels in each group.
Group n CTn栺(毺g/mL) CK-MB (U/L) hsCRP (U/L)
A 12 110.35依25.96        134.75依35.12 47.10依2.82
B 12   182.37依30.46△      214.52依43.78△      77.35依1.32△    
C 12   120.53依31.03★      142.36依40.13★    50.24依1.47★
D 12   136.42依28.37★     157.21依45.91★     53.38依1.56★
Note: ★P<0.01, vs. ischemia/reperfusion group; △P<0.01, vs. sham 
operation group. 
3.2. Effects of rosiglitazone on plasma NO, ET and GSH-Px 
levels in rabbits with myocardial ischemia/reperfusion injury 
  Compared with sham operation group, plasma NO and 
GSH-Px levels were significantly decreased, while plasma 
ET level was significantly increased in the ischemia/
reperfusion group. Compared with ischemia/reperfusion 
group, plasma NO and GSH-Px levels were significantly 
increased and plasma ET level was significantly decreased 
in the rosiglitazone high and low dose groups. There were no 
significant differences in plasma NO, ET and GSH-Px levels 
between rosiglitazone high and low dose groups (Table 2). 
Table 2
Plasma NO, ET and (GSH-Px levels in each group.
Group n NO(毺mol/L)  ET (pg/mL) GSH-Px(U)
A 12 71.28依4.32                 40.23依6.35 218.23依21.75
B 12 32.51依5.25△              297.57依7.58△ 112.42依31.58△
C 12 65.84依5.05★             121.28依8.82★▲      187.34依27.29★★▲ 
D 12 57.32依6.34★★        143.56依6.54★ 176.56依33.81★★   
Note: ★★P < 0.05, ★P < 0.01, vs. ischemia/reperfusion group; △P < 
0.01, vs. sham operation group; ▲P > 0.05, vs. rosiglitazone low dose 
group.
3.3. Effects of T-SOD and MDA levels in rabbits with 
myocardial ischemia/reperfusion injury 
  Compared with sham operation group, plasma MDA level 
was significantly increased and plasma T-SOD level was 
significantly decreased in the ischemia/reperfusion group. 
Compared with ischemia/reperfusion group, plasma MDA 
level was significantly decreased and plasma T-SOD level 
was significantly increased in the rosiglitazone high and low 
dose groups (Table 3).  
Table 3
Plasma MDA and ET levels in each group.
Group n T-SOD(U/L) MDA(nmol/mL)
A 12 521.38依34.42                                            7.14依0.42
B 12 390.54依33.86△△              12.84依0.79△
C 12 489.27依15.62★★                7.46依0.37★   
D 12 454.58依25.43★★                 8.10依0.54★
Note: ★P<0.05, ★★P<0.01, vs. ischemia/reperfusion group; △P< 
0.05, △△P<0.01, vs. sham operation group. 
3.4. Optical microscope observation of pathological structure 
  Through the optical microscopy, in the sham operation 
group, myocardial fibers were orderly arranged, and no 
invasion of inflammatory cells in the myocardial interstitium 
was observed; in the rosiglitazone high and low dose 
groups, nuclei of myocardial cells were uniform in size and 
distribution, but myocardial fibers exhibited slight swelling, 
and fibrocytes and inflammatory cells invaded occasionally; 
in the ischemia/reperfusion group, myocardial fibers were 
swollen and disordered, a large number of inflammatory 
cells invaded the myocardial interstitium, and obvious local 
necrosis was even observed.  
Figure 1. Optical microscope observation of pathological structure.
Group A: full of muscle fiber, the nuclear shape is normal.
Group B: extensive necrosis, muscle fiber fracture, severe muscle cell nucleus dissolved, disappear, neutrophils large seepage.
Group C: myocardial cell nuclei are uniform and mild myocardial fibers swelling, occasional fibroblast cells and inflammatory cells infiltration.
Group D: myocardial cell nuclei are uniform and mild myocardial fibers swelling, occasional fibroblast cells and inflammatory cells infiltration.
Group A                                                          Group B                                                            Group C                                                              Group D
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  Sham operation group: intact muscle fiber and normal 
nuclear morphology.
  Ischemia/reperfusion group: wide necrosis, muscle fiber 
was greatly broken, a large number of myocyte nuclei 
dissolved or disappeared, and many neutrophil granulocytes 
effused. 
  Rosiglitazone high and low dose groups: myocyte nuclei 
were uniform in size, myocardial fiber was slightly swollen, 
and fibroblasts and inflammatory cells invaded occasionally 
(Figure 1).  
                                         
4. Discussion
  Acute myocardial infarction is recently a leading health- 
or life-threatening disease, and myocardial ischemia/
reperfusion can cause irreversible damage to, even death 
or apoptosis of, injured myocardial cells, which further 
aggravates myocardial damage and increases mortality[9,10]. 
There is evidence that various inflammatory factors, 
including neutrophil, monocyte, mastocyte, macrophage, 
tumor necrosis factor-毩, interleukin-1, -6, and -8 
participate in myocardial ischemia/reperfusion[11-13]. 
Protein-protein interaction between PPAR-毭 and nuclear 
factor 毷B (NF-毷B) effectively inhibits homogenous cis-
element binding in the promoter region of NF-毷B and 
inflammatory factor genes[14-16]. 
  PPAR-毭 is expressed in many immunocytes and PPAR-
毭 ligand 15d-PGJ2 regulates various immunological 
responses. PPAR-毭 even in a very low concentration of 
15d-PGJ2 can inhibit lipopolysaccharide-induced or NF-
毷B-, STAT1- and activator protein 1 (AP-1)-mediated 
transcription[17,18]. Both 15d-PGJ2 and rosiglitazone can 
inhibit the production of PPAR-毭, thereby inhibiting 
interleukin-2 gene expression and PHA-induced human T 
cell proliferation, and finally hampering homogenous cis-
acting element binding in the promoter region between 
activated T cells and interleukin-2[19-21]. In addition, PPAR-
毭 also regulates the differentiation of some immunocytes, 
including T cells, mononuclear macrophages and nature 
killer cells. PPAR-毭 ligand inhibits the production of 
interferon-毭 in natural killer cells and T cells by PPAR
毭-dependent and non-dependent approach. Gene chip 
technique showed that PPAR毭 expression was 5-8 times 
greater in type 2 T cells than in type 1 T cells[22-24]. After 
addition of interleukin-4 and interferon-毭 antibodies, 
type 2 immunocytes can induce PPAR-毭 expression in 
natural killer cells. The activated PPAR-毭 can successfully 
inhibit the expression of inflammatory factors, including 
tumor necrosis factor-毩, and interleukin-1, -2 and -6 
in monocytes, exhibiting anti-inflammatory effects. An 
effective control of interleulin-2 gene expression in the 
early stage of lymphocyte differentiation is very important 
for activation of lymphocytes. The activated PPAR-毭 can 
effectively inhibit interleukin-2 gene expression and prevent 
the early activation of T lymphocytes, thereby exerting anti-
inflammatory effects[25,26]. 
  Results from this study showed that pretreatment with 
PPAR-毭 agonist rosiglitazone can significantly increase 
plasma SOD, GSH-Px and NO levels and decrease plasma 
cTNI, CK-MB, hsCRP, MDA and ET levels, significantly 
decrease the incidence of arrhythmia, reduce myocardial 
infarct volume, protect cardiocyte mitochondrial function, 
and maintain intact mitochondrial ultrastructure in a rat 
model of myocardial ischemia/reperfusion injury. 
  Based on the present results, we can infer that rosiglitazone 
pretreatment can protect myocardium and alleviate ischemia/
reperfusion injury. However, the precise mechanism remains 
unclear. Rosiglitazone, as a PPAR-毭 agonist, influences the 
formation and activation of inflammatory cells or inflammatory 
factors and simultaneously inhibits the expression of monocyte 
chemoattractant protein-1, intercellular adhesion molecule-1 
and inducible nitric oxide synthase by regulating PPAR-
毭 expression[27,28]. In addition, Khandoudi et al[30] found 
that thiazolidinediones can inhibit c-Jun amino-terminal 
kinase phosphorylation and activator protein-1 DNA 
binding activity, and thereby alleviate myocardial ischemia/
reperfusion injury and improve cardiac function.
  Taken together, rosiglitazone can be used to treat myocardial 
ischemia/reperfusion injury by inhibiting inflammatory 
reaction, improving endothelial function, and reducing reactive 
oxygen species. Nevertheless, the precise mechanism will be 
further studied. 
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